Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06058156 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT06058156 is a Phase 2 study that was terminated before completion, run by Sanofi. The registered enrollment target is 70 participants.
The verdict
NCT06058156, a Phase 2 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic therapy. Participants will be randomized to receive SAR444656 dose 1, dose 2, dose 3 or matching placebo. Participants who meet inclusion/exclusion criteria will be stratified for randomization by severity of AD (moderate \[baseline EASI score \<22\] versus severe \[baseline EASI score ≥22\]). The total duration of study is approximately 24 weeks, including 1 to 4 weeks for screening, 16 weeks for double-blind study treatment and 4 weeks for follow-up.
Interventions
- DRUG Placebo
- DRUG SAR444656 (KT-474)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2025-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06058156
The ClinicalTrials.gov registry entry for NCT06058156 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06058156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06058156 about?
NCT06058156 is a clinical study titled "Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis". This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic t...
What is the current status of trial NCT06058156?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2023-11-09. Estimated completion is 2025-11-20.
What interventions are being tested in trial NCT06058156?
The interventions under investigation include: Placebo (DRUG), SAR444656 (KT-474) (DRUG).
Who is sponsoring clinical trial NCT06058156?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.